BEAM
Beam Therapeutics Inc.
Biotechnology · Healthcare · United States
27.23
close · 2026-10-30
value
64
cheaper than peers64
quality
76
stronger fundamentals76
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -0.9% | 81 |
| earnings yield, latest year | -3.0% | 71 |
| earnings yield, 2 years ago | -6.3% | 70 |
| price to book | 2.55× | 64 |
| cash flow yield, 2 years ago | -6.5% | 56 |
| earnings yield, 3 years ago | -15.2% | 50 |
| earnings yield, 1 year ago | -16.8% | 49 |
| cash flow yield, latest year | -12.8% | 45 |
| cash flow yield, 1 year ago | -12.7% | 43 |
| price to sales | 17.15× | 40 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 324.9% | 89 |
| return on equity | -5.8% | 79 |
| debt to equity | 21.5% | 46 |
| operating margin | -337.8% | 39 |
4 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$233.6M |
| employees | 522 |
| first trade | 2020-02-06 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.81 | -4.58 | -1.72 | -4.13 |
| free cash flow | -$360.0M | -$356.2M | -$182.9M | -$26.4M |
| net income | -$80.0M | -$376.7M | -$132.5M | -$289.1M |
| revenue | $139.7M | $63.5M | $377.7M | $60.9M |
| unusual items | $4.8M | -$10.2M | -$1.4M | $63.0M |